After two days of hearings, the Pharmacy Compounding Advisory Committee voted to recommend that six out of seven proposed peptides move to the 503A bulk drug compounding list
50mg Per Capsule Oral Administration NNMT Target Enzyme 22+ BHRC Locations Available Option An oral NNMT inhibitor designed to support cellular energy metabolism and metabolic function through targeted enzyme modulation
Supports neurotransmitter synthesis, is anti-inflammatory, and is especially useful for mood disorders, depression, dementia, PMS, skin disorders, and neuropathy
doi:10.2147/IDR.S346705 [31] Rezaei M, Javadmoosavi SY, Mansouri B, Azadi NA, Mehrpour O, Nakhaee S
Verified buyer Feb 2026 See all 784 reviews
AOD9604 supplementation had no adverse effects compared to full-length hGH treatment